Global /United States /Healthcare /Diagnostics & Research /LLA

LungLife AI, Inc.

LLA

• LSE: LLA • Delayed

6GBX -63%

0.0738 USD

As of 5 June 2026, LungLife AI, Inc. has a market cap of $1.71M USD, ranking #47509 globally and #6031 in the United States. It ranks #4214 in the Healthcare sector, and #21 in the Diagnostics & Research industry.

Global Rank

47509

Country Rank

6031

Sector Rank

4214

Industry Rank

Key Stats

Market Cap

$1.71MUSD

1.27M GBP

Enterprise Value

-$849.87KUSD

-633.05K GBP

Revenue (TTM)

$30.79KUSD

22.95K GBP

EBITDA (TTM)

-$4.63MUSD

-3.45M GBP

Net Income (TTM)

-$4.74MUSD

-3.53M GBP

PS Ratio

55.4

PB Ratio

0.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Paul Pagano open_in_new

Employees

Founded

2009

Website

lunglifeai.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-63%	0%	-29%	-63%	-63%	-63%	-83%	-83%	-83%

News

Markets

Exchange	Ticker	Price	Quotes
London Stock Exchange (LSE / LON) MIC: XLON PRIMARY	LLA LungLife AI Inc Ordinary Shares - Reg S ISIN: USU5500L1128 Shares Out.: Shares Outstanding: 25.486M¹ Shares Float: 25.428M² TV: TradingView: LSE: LLA SA: Stock Analysis: LON: LLA YF: Yahoo Finance: LLA.L GF: Google Finance: LON: LLA BA: Barron's: LLA MS: Morningstar: XLON: LLA	6 GBX	TV: TradingView: LSE: LLA SA: Stock Analysis: LON: LLA YF: Yahoo Finance: LLA.L GF: Google Finance: LON: LLA BA: Barron's: LLA MS: Morningstar: XLON: LLA
London Stock Exchange (LSE / LON) MIC: XLON	LLAI LungLife AI Inc ISIN: USU5500L1045 TV: TradingView: LSE: LLAI SA: Stock Analysis: LON: LLAI YF: Yahoo Finance: LLAI.L GF: Google Finance: LON: LLAI BA: Barron's: LLAI MS: Morningstar: XLON: LLAI	4 GBX	TV: TradingView: LSE: LLAI SA: Stock Analysis: LON: LLAI YF: Yahoo Finance: LLAI.L GF: Google Finance: LON: LLAI BA: Barron's: LLAI MS: Morningstar: XLON: LLAI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About LungLife AI, Inc.

LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.

Similar Companies

Industry: Diagnostics & Research (United States)

Name	Market Cap (USD) diff.	PE	Country
Quest Diagnostics Inc. NYSE: DGX	$20.96B 1M%	20.9	United States
Exact Sciences Corp. NASDAQ: EXAS	$20.03B 1M%	-	United States
Chrome Holding Co. OTCMKTS: MEHCQ	$96.4M 6K%	-	United States
Enzo Biochem, Inc. OTCMKTS: ENZB	$36.59M 2K%	-	United States
Psychemedics Corp. OTCMKTS: PMDI	$13.46M 689%	-	United States
Star Equity Holdings, Inc. NASDAQ: STRR	$6.89M 304%	-	United States

Industry: Diagnostics & Research (Global)

Name	Market Cap (USD) diff.	PE	Country
Q Qiagen N.V. FRA: QIA	$8.5B 7.3B EUR 498K%	20.2	Netherlands
Global Cord Blood Corp. OTCMKTS: CORBF	$73.65M 4K%	0.8	Hong Kong
DNA Chip Research Inc. TSE: 2397	$46.18M 7.39B JPY 3K%	-	Japan
Premium Healthcare Group EGX: PHGC	$41.85M 2.17B EGP 2K%	-	Egypt
SLS BIO Co., Ltd. KRX: 246250	$17.49M 26.89B KRW 925%	-	South Korea
Longduoduo Company Ltd. OTCMKTS: LDDD	$15.31M 797%	-	China

chevron_leftBack